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Abstract
The canine vector-borne infectious diseases (CVBDs) are an emerging problem in veterinary medicine and the
zoonotic potential of many of these agents is a significant consideration for human health. The successful
diagnosis, treatment and prevention of these infections is dependent upon firm understanding of the underlying
immunopathology of the diseases in which there are unique tripartite interactions between the microorganism, the
vector and the host immune system. Although significant advances have been made in the areas of molecular
speciation and the epidemiology of these infections and their vectors, basic knowledge of the pathology and
immunology of the diseases has lagged behind. This review summarizes recent studies of the pathology and host
immune response in the major CVBDs (leishmaniosis, babesiosis, ehrlichiosis, hepatozoonosis, anaplasmosis,
bartonellosis and borreliosis). The ultimate application of such immunological investigation is the development of
effective vaccines. The current commercially available vaccines for canine leishmaniosis, babesiosis and borreliosis
are reviewed.
Introduction
Vector-borne diseases affecting the domestic dog are of
major global significance for their impact on the health
and well being of these companion and working ani-
mals, and also because for some of these diseases the
dog acts as a reservoir species for infection of the
human population. The most significant of these dis-
eases are bacterial and microparasitic and these are
summarized in Table 1. These diseases have received
the attention of the veterinary and public health
research communities in recent years and progress in
such research forms the focus of the annual series of
Canine Vector-Borne Disease (CVBD) workshops hosted
b yB a y e ra n dn o ws u m m a r i z e di nt h ep a g e so ft h i s
journal.
The greatest research activity has focussed on the
molecular speciation of the infectious agents, definition
of their parasite vectors, the geographical distribution
and movement of agents and vectors, the clinical syn-
dromes expressed by infected dogs and people and ele-
ments of the pathogenicity of the causative organisms.
The more challenging aspect for research remains an
exploration of the pathology and secondary
immunopathology established in dogs by these infec-
tions and the nature of the immune response made by
the canine host to the pathogens. There are practical
reasons why this important area of research has been
poorly addressed to date, including: (1) the ethics and
expense of working with the dog as an experimental ani-
mal, (2) the problem, for some diseases, of establishing
reliable and repeatable in-vivo model systems, (3) the
challenges in assembling significantly large populations
of spontaneously-infected and well-characterized clinical
populations, (4) the availability of appropriate immuno-
logical reagents and molecular methodology for dissec-
tion of the canine immune response relative to such
investigations in man or laboratory rodents, and (5) the
difficulty in attracting appropriate research funding for
the investigation of canine disease. With the publication
o fv e r s i o n so ft h ec a n i n eg e n o m e[ 1 ]t h e r eh a v eb e e n
rapid advances with respect to investigative technology
for canine immunopathological research, so this is now
less of an insurmountable problem. Numerous studies
have shown the utility of the reverse transcriptase poly-
merase chain reaction (RT-PCR) for exploring the tissue
expression of targeted genes [2], although the applica-
tion of methods such as mRNA expression microarrays
[3] and genome wide association studies (GWAS) [4,5]
remain costly options.
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rent state of knowledge regarding the pathology and
immunology of CVBD in the host species. The review will
focus on key diseases and cannot be exhaustive, but should
give a feel for the current state-of-the-art in this important
area of veterinary medicine. It should be noted that the
scope of the review does not include the equivalent feline
infections and that for at least one of these (feline bartonel-
losis; [6]) knowledge of immunopathology has progressed
beyond that currently described for the dog.
Table 1 Major canine vector-borne diseases
Infectious Agent Arthropod Vectors Zoonotic Potential Reference
Leishmania infantum Phlebotomus sandflies
(old world)
Dog is major reservoir of infection [17]
(Leishmania chagasi) Lutzomyia sandflies
(new world)
Babesia vogeli Rhipicephalus
sanguineus
Not with canine pathogens [103]
Babesia canis Dermacentor spp.
Babesia rossi Haemaphysalis leachi
Other large Babesia
Babesia gibsoni Haemaphysalis spp.
Rhipicephalus
sanguineus?
Babesia conradae Unknown
Babesia microti-like (also known as
Theileria annae)
Ixodes hexagonus
(suspected)
Hepatozoon canis Rhipicephalus
sanguineus
Unlikely due to mode of transmission (ingestion of vector) [104]
Hepatozoon americanum Amblyomma
maculatum
Ehrlichia canis Rhipicephalus
sanguineus
E. ewingii and E. chaffeensis are human pathogens, but role of the
dog as a reservoir is unproven; human infections with E. canis are
reported
[105,106]
Ehrlichia ewingii Amblyomma
americanum
Ehrlichia chaffeensis Amblyomma
americanum
Anaplasma phagocytophilum Ixodes ricinus Important human pathogen [105-107]
Anaplasma platys Rhipicephalus
sanguineus
(suspected)
None recognized unequivocally [105,106]
Rickettsia rickettsii (Americas) Dermacentor
andersoni
Important human pathogen; people may become infected whilst
removing engorged ticks from dogs; dogs maintain infested tick
population in the domestic environment
[105]
Dermacentor variablis
Rickettsia conorii (Europe, Asia, Africa) Rhipicephalus
sanguineus
Borrelia (multiple species but primarily
B. burgdorferi sensu stricto, B. garinii and
B. afzelii)
Ixodes ticks (multiple
species)
Dog is an ‘accidental host’ but may carry ticks into the domestic
environment
[108,109]
Bartonella vinsonii subspecies berkhoffii Ticks proposed (fleas
for cats)
Unknown if dogs are competent reservoirs; B. vinsonii subsp. berkhoffii
(predominant canine isolate) is a rare cause of human infections
[36,40]
Bartonella henselae
Bartonella clarridgeiae
Bartonella rochalimae
Bartonella quintana
Bartonella washoensis
Dirofilaria immitis Mosquitoes Rare human infections; incidental host [110]
Mycoplasma haemocanis Candidatus
Mycoplasma haematoparvum
Rhipicephalus
sanguineus (proposed)
No evidence for human infection [111]
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Page 2 of 13Unique aspects of the canine vector-borne
diseases
In addition to the practical issues defined above, sim-
p l ea s p e c t so ft h en a t u r eo ft h eC V B D sm a k et h e m
particularly challenging for investigation. All of these
infections are characterized by being formed of a
unique triad that involves the infectious agent, the vec-
tor of that agent and the host animal (Figure 1) [7,8].
In many instances this integral and complex three-way
relationship has likely evolved over millennia with fas-
cinating selective advantages conferred by some
aspects of the relationships. For example, the infectious
agents are known to be able to manipulate the physiol-
ogy (gene expression) and behaviour of the arthropod
vectors to ensure their transmission [9] and during the
process of taking a blood meal the arthropod vectors
appear to be able to manipulate the host immune sys-
tem through the release of potent salivary immunomo-
dulators, thereby conferring an advantage to the
co-transmitted microorganism in terms of establish-
ment of disease and further transmission to naïve co-
feeding vectors via the process of ‘saliva-activated
transmission’ [8,10]. This group of infectious agents is
also characterized by the ability to induce chronic or
recrudescent disease in the canine host, likely by occu-
pying particular tissue niches where they may be pro-
tected from the host immune response, or by
manipulating host immunity to prevent a sterilizing
response and permit persistent infection. The clinico-
pathological changes in any one dog may be compli-
cated by the co-infections that may occur in endemic
areas (e.g. combinations of leishmaniosis, monocytic
ehrlichiosis and babesiosis; or borreliosis and anaplas-
mosis). Finally, the nature of the clinical signs
expressed by the infected dog often relate to secondary
immunopathology (e.g. the induction of autoantibodies
or formation and deposition of immune complexes of
antigen, antibody and complement) rather than direct
cellular or tissue damagea n dt h ea c c o m p a n y i n g
inflammatory response. With all of these complex
interrelationships, our greatest knowledge gap relates
to what is happening within the infected canine host.
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Figure 1 The triad of canine vector-borne disease. The canine vector-borne diseases are characterized by the unique three-way interaction
between the infectious agent, the vector and the host immune system. Vector salivary proteins injected into the dermal microenvironment
during taking a blood meal modulate the host immune system creating a favourable environment for survival and replication of the infectious
agent. This permits infection of co-feeding naïve vectors. The effects on host immunity are often to promote Th2-regulated humoral responses
above the protective Th1-regulated cellular immune response. This allows persistence of the infection and encourages the development of
inappropriate secondary immunopathology characterized by hypergammaglobulinaemia, autoantibody and immune complex formation.
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Page 3 of 13The pathology of canine vector-borne diseases
T h es i m p l ep a t h o l o g yo ft h eC VBDs is relatively poorly
described. Few investigations have ever been made of
the primary site of interaction of the agent-vector-host
triad, i.e. the cutaneous site of vector attachment and
feeding, which also represents the site of transmission of
the agent and the point of initial engagement with the
host immune system. The histopathology of canine cuta-
neous tick-attachment sites has been described at the
light microscopical level, including the central dermal
cone-shaped zone of necrosis related to insertion of tick
mouthparts and formation of ‘cement’ and the sur-
rounding mixed chronic inflammatory infiltration of
macrophages, lymphocytes, plasma cells, neutrophils and
eosinophils [8,11]. However, given the increasing range
of species-specific and cross-reactive reagents now avail-
able for immunohistochemical evaluation of canine tis-
sue immune responses [12] it is surprising that the
temporal kinetics and nature of these inflammatory
responses has not been further defined. Such studies
have been performed recently in sheep exposed twice to
Hyalomma ticks, in which cutaneous attachment sites
and regional draining lymph nodes had infiltration of
CD1
+ dendritic cells, CD8
+ cytotoxic T lymphocytes and
T cells bearing the gδ form of the T-cell receptor [13].
There have been numerous reports of the cutaneous
pathology in the chronic stages of canine leishmaniosis
(Figure 2) and in some of these the presence of intracel-
lular amastigotes within the macrophages forming the
granulomatous dermatitis has been highlighted immuno-
histochemically [14,15]. Immunohistochemical studies
have also shown that in the relatively milder clinical
lesions of exfoliative dermatitis there is a low parasite
burden, associated with enhanced expression of class II
molecules of the major histocompatibility complex
(MHC) by keratinocytes and a dermal T-cell infiltrate
dominated by CD8
+ cells over the CD4
+ Th e l p e r( T h )
subpopulation. In contrast, with increasing severity of
cutaneous disease (the nodular form) there is reduced
expression of class II molecules of the MHC by epider-
mal Langerhans cells and keratinocytes and fewer infil-
trating T lymphocytes [16,17]. The lymph nodes of
asymptomatic Leishmania-infected dogs are hyperplas-
tic, but when disease becomes symptomatic there is
more often atrophy of the lymph node cortex [18].
Limited investigations have been performed on the
systemic pathological changes that accompany these dis-
eases in spontaneously- or experimentally-infected dogs.
Again, the most reported are the lesions that develop in
canine leishmaniosis [19], for example the granuloma-
tous inflammatory infiltrates that form with foci of
infection in organs such as the liver [20] (Figure 3), and
the range of secondary immunopathological (e.g.
immune complex-mediated) lesions that arise in the
renal glomeruli [21-23] (Figure 4), the nasal mucosa
[24] or the uveal tract of the eye [25,26]. Immunohisto-
chemistry has been used in several studies to determine
the parasite load of infected tissues [27].
Pathological descriptions have also been made of the
synovial, renal (’Lyme nephropathy’) and nervous system
lesions in canine borreliosis [28,29]. The renal lesions are
characterized by glomerulonephritis (with immunoglobu-
lin [Ig] G, IgM and complement C3 subendothelial
immune complex deposition), interstitial nephritis and
tubular necrosis [29]. A detailed histopathological descrip-
tion of the lesions in dogs infected experimentally by
Figure 2 Canine leishmaniosis. Skin biopsy from a dog with
symptomatic visceral leishmaniosis. There is a mixed chronic
inflammatory infiltration of the dermis associated with numerous
macrophages laden with amastigotes (arrows). Haematoxylin and
eosin, bar = 50 μm.
Figure 3 Canine leishmaniosis. Section of liver from a dog with
visceral leishmaniosis. There is a discrete focus of granulomatous
inflammation within the mid-zonal hepatic parenchyma.
Macrophages within the focus will contain amastigotes.
Haematoxylin and eosin, bar = 50 μm.
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Page 4 of 13exposure to infected ticks has been reported. These ani-
mals developed mixed inflammatory dermatitis at the site
of tick attachment, hyperplasia within the draining lymph
node and synovitis of nearby forelimb joints. The synovial
reaction was either predominantly an acute neutrophilic
inflammation with intraarticular fibrin deposition or a
chronic lymphoplasmacytic reaction with plasma cells
dominating over CD3
+ T cells. Perineuritis and periarteri-
tis were also described in the periarticular tissue [30]. In
another experimental infection study, lymphoplasmacytic
meningitis was also recorded in 3/20 infected dogs [31].
The bone marrow changes in chronic monocytic ehrli-
chiosis have been reported [32]. Dogs infected experi-
mentally with Ehrlichia canis develop lymphoplasmacytic
uveitis and meningitis [33] and experimental infection
with Anaplasma phagocytophilum leads to splenic hyper-
plasia and mild non-specific reactive hepatitis [34]. The
spectrum of Bartonella-associated inflammatory changes
in individual canine patients, particularly dogs with endo-
carditis [35-40], has been described. The pathology of
lesions of skeletal muscle [41] and the periosteum [42]
has been described in dogs infected by Hepatozoon amer-
icanum. These are all primarily light microscopical
descriptions and the lesions await further exploration by
immunohistochemistry or characterization of lesional
gene expression via RT-PCR or microarray investigation
of fresh-frozen tissue extracts.
The immunology of canine vector-borne diseases
Understanding of the immune response to infection has
expanded greatly in recent years and, as for many
aspects of immunology, this new knowledge is based on
application of the discovery of multiple functional
subsets of T lymphocytes expressing the CD4 co-recep-
tor molecule. The diversity in regulatory T-cell subsets
(Figure 5) is best characterized in experimental rodents
and man. Following the initial description of Th1 and
Th2 cells by Mossman et al. [43] much of the early
work defining the interrelationships between these
populations was performed using the murine model of
dermatotropic leishmaniosis. In this model there was
clear dichotomy between the protective Th1 immune
response in disease-resistant C57Bl6 mice and the Th2
response made by susceptible BALB/c mice [44]. More
recently, the murine model system has enabled defini-
tion of the role of regulatory T lymphocytes (Treg) in
chronic infections such as leishmaniosis. These cells
inhibit the function of Th1 cells allowing persistence of
infection, but more importantly limit the development
of secondary immunopathology. In murine models it
has also been suggested that effector Th1 cells may
become a source of the key regulatory cytokine, inter-
leukin (IL)-10, for the same reason [45] (Figure 6).
The CD4 Th subset paradigm has also been used as a
framework for understanding the immunomodulatory
properties of arthropod salivary proteins released into
the host dermal microenvironment upon taking a blood
meal. Arthropod saliva is not only anticoagulant and
anti-inflammatory in nature, but also contains potent
immunomodulators that are now being characterized
and purified. In general terms, the effect of these sali-
vary molecules is to alter the host immune response
within the skin and possibly also within draining lym-
phoid tissue. These molecules tend to promote Th2
immunity while suppressing the Th1 response. This pro-
vides a more favourable environment for the establish-
ment of intracellular infection (for which Th1 immunity
is the appropriate means of clearance of infection) and
at the same time pushes immune balance towards con-
ditions favouring secondary humoral immunopathology
(e.g. autoantibody and immune complex formation) [8].
Few studies have examined the effect of arthropod sali-
vary proteins on the canine immune system. Salivary
gland extract from Rhipicephalus sanguineus co-cultured
with canine peripheral blood mononuclear cells sup-
pressed the production of total immunoglobulin and
IgA (but not IgM) by lymphocytes stimulated with
pokeweed mitogen or lipopolysaccharide [46].
For leishmaniosis, clear parallels were recognized
between the susceptibility and resistance phenotypes in
murine strains and in natural infection of the dog. Rela-
tively early studies confirmed that the resistance of cer-
tain dogs to severe clinical leishmaniosis was also
determined by a Th1 immune response with production
of the key Th1 cytokine interferon (IFN)-g [47]. Leish-
maniosis has since become the single best understood
vector-borne disease of the dog as it has rightly
Figure 4 Canine leishmaniosis. Section of kidney from a dog with
visceral leishmaniosis. There is marked lymphoplasmacytic interstitial
nephritis with obliteration of the glomerulus and afferent and
efferent arterioles by granulomatous inflammatory infiltration.
Haematoxylin and eosin, bar = 100 μm.
Day Parasites & Vectors 2011, 4:48
http://www.parasitesandvectors.com/content/4/1/48
Page 5 of 13attracted appropriate funding commensurate with the
significance of the canine disease for human health.
Numerous investigations have confirmed the importance
of Th1 immunity and further characterized cytokine
gene expression in this disease. Asymptomatic sponta-
neously-infected dogs have greater expression of genes
encoding IFN-g and tumour necrosis factor (TNF)-a
and a lower parasite burden within lymph nodes, com-
pared with symptomatic dogs with high parasite burdens
in which there is greater expression of genes encoding
the immunosuppressive cytokines IL-10 and transform-
ing growth factor (TGF)-b [48]. In contrast, within the
spleen there was no clear difference in IFN-g,I L - 4a n d
IL-12 gene expression between asymptomatic and symp-
tomatic dogs [49], but splenic IL-10 mRNA expression
was greater in symptomatic dogs [50]. There was no
clear evidence for higher expression of IL-10 mRNA in
the bone marrow or blood lymphocytes of infected ver-
sus uninfected or symptomatic versus asymptomatic
dogs [51,52]. A study of cytokine gene expression using
RNA extracted from formalin-fixed tissue biopsies and
real-time RT-PCR has shown elevation of mRNA encod-
ing IL-4, IFN-g and TNF-a compared with normal skin,
but an association between cutaneous parasite burden
and severity of skin lesions with only IL-4 gene expres-
sion. This was interpreted to suggest a Th2 bias within
the cutaneous lesions [53].
Overall, these cytokine gene expression studies suggest
that symptomatic infected dogs have insufficient Th1
(IFN-g) with enhanced Treg (IL-10) activity, however
interpretation of these investigations should be tem-
pered by the facts that: (1) there is little standardization
of the disease (e.g. spontaneous versus experimental
infection, breed of dog, geographical setting, infectious
load etc.), (2) there is variation in the body compart-
ment tested (e.g. blood, lymph node, spleen, bone mar-
row or skin), (3) most of the studies employ
conventional gel-based RT-PCR rather than real time
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Figure 5 CD4
+ T-cell subsets. There is increasing complexity in the network of functional CD4
+ T-cell subsets. Under the influence of specific
promoting cytokines (purple lettering) and transcription factors (not shown here), the naïve T cell may differentiate towards a functional subset
promoting either cell-mediated and proinflammatory immunity (Th1, Th17 and Th9; black lettering), humoral immunity (Th2 and T follicular
helper [TFh]; green lettering) or a suppressive response (induced Treg and Treg1; blue lettering). These subsets are not strongly polarized and
there is considerable ‘plasticity’ in their actions, whereby one cell type can be reprogrammed to another at a different stage of the immune
response. This is readily seen by the ability of multiple of the subsets to produce the immunosuppressive cytokine IL-10. The natural Treg appear
separately, as this committed lineage leaves the thymus directly and is responsible for the control of allergen- and autoantigen-specific
lymphocytes.
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Page 6 of 13RT-PCR employing multiple housekeeper genes for rela-
tive determination of copy number [54], and (4) gene
expression rather than protein production is measured.
In the peripheral blood of symptomatic dogs there is a
reported reduction in the proportions of circulating
CD21
+ B cells and CD14
+ monocytes compared with
asymptomatic dogs in which the major alteration is an
elevation in the frequency of CD8
+ T cells [55]. How-
ever, these data are controversial, as other studies have
shown no difference in the proportions of different
blood lymphocyte subpopulations between normal and
infected dogs and in infected symptomatic dogs
throughout the course of medical therapy [56]. The
lymph nodes of Leishmania-infected dogs have propor-
tionally more CD8
+ T cells, reduced B cells and upregu-
lation of MHC class II expression by lymphoid cells
[18].
It has proven much more challenging to clearly relate
the subisotype of the IgG antibody response to clinical
status. Although there are clear associations between
murine Th1 and IgG2a responses and Th2 and IgG1
responses, there is no consensus as to whether canine
humoral immune responses are polarized in leishmanio-
sis. The confusion partly arises from inconsistency in
nomenclature and the validity and specificity of reagents
produced for the detection of canine IgG subclasses
[57,58].
The genetic basis for protective immunity as recog-
nized in particular breeds (e.g. the Ibizian hound and
dogs raised in endemic areas) [59] has been explored by
characterizing associations with genes of the canine
MHC (the DLA system; specifically the DLA class II
allele DLA-DRB1*01502) [60] and genes identified as
associated with resistance in other species (Slc11a1
encoding the natural resistance associated protein 1
[NRAMP1]) [61]. A recent study has failed to confirm
sequence differences in Slc11a1 between symptomatic
and asymptomatic naturally-infected dogs [49]. The
most exciting current investigation of canine leishma-
niosis is that which forms one of the work packages of
the European Union-funded LUPA project http://www.
eurolupa.org/, in which susceptibility and resistance is
being examined via GWAS studies of significant num-
bers of dogs with clinically well-characterized infection
status and disease.
In contrast to leishmaniosis, the host immune
response to the remaining major canine vector-borne
pathogens is relatively poorly characterized. Logically,
most of the focus for these infections has been on
understanding the humoral immune response in order
to develop serological diagnostic methods for detection
of individual cases or population epidemiological stu-
dies. The combination of serology and PCR detection
now forms the cornerstone for diagnosis in most of the
C V B D s ,b u ti ti sb e y o n dt h es c o p eo ft h i sr e v i e wt o
detail studies of the kinetics of the humoral immune
response in the CVBDs.
There has been very limited exploration of other
aspects of the immune response in these diseases; in
particular how these infections might map to the CD4 T
cell immunoregulatory model described above for leish-
maniosis. Mixed breed dogs infected experimentally
with E. canis and monitored for 4 months post infection
had no significant changes in the concentration of
serum IgG, IgM and IgA, the percentage of circulating
CD4
+ T cells or the in-vitro function of blood lympho-
cytes (as determined by mitogen stimulation and the
ability of lymphokine-activated killer cells to cause lysis
of a
51Cr-labelled target monocyte cell line). A transient
elevation in blood CD8
+ T cells was found at 6 weeks
post infection [62]. Whilst the study of T cell and cyto-
kine responses may not be crucial for diagnosis of the
CVBDs, such knowledge should underpin the develop-
ment of vaccines and immunotherapeutic approaches to
the management of these infections.
In addition to the host immune response to the vec-
tor-borne agents, an important part of the pathogenesis
of these infections often involves the secondary
immune-mediated sequela that are manifestations of
immune dysregulation induced by the organism and/or
the vector [7]. Many of the CVBDs are characterized by
serum hypergammaglobulinaemia and the production of
circulating immune complexes or autoantibodies (e.g.
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Figure 6 Plasticity of CD4
+ T-cell subsets. The plasticity of CD4
+
T-cell subsets is demonstrated in the murine model of
leishmaniosis. In many chronic infectious diseases it is now
recognized that sterilizing immunity is prevented by the action of T
cells with regulatory function. Although regulatory T cells prevent
complete elimination of the infection, they are crucial in inhibiting
the development of secondary immunopathology. A balance is
therefore achieved between infection-limiting Th1 immunity and
immunopathology-limiting regulation. The regulatory activity might
come from classical induced or natural Treg, but equally some
Leishmania-specific Th1 cells may be re-programmed to become IL-
10 producing regulatory cells.
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Page 7 of 13antierythrocyte and antiplatelet antibodies, antinuclear
antibodies) that play a role in disease pathogenesis.
Immune complex deposition and autoantibody forma-
tion is widely recognized in the pathogenesis of canine
leishmaniosis [63-65] and monocytic ehrlichiosis [66,67].
In the latter disease, both platelet-bound and serum pla-
telet-bindable antibodies have been demonstrated
[68,69], in addition to antinuclear antibodies and antier-
ythrocyte antibodies [70]. Dogs with A. phagocytophilum
infection have also been reported as being Coombs posi-
tive and having platelet-bound antibodies [71,72]. Simi-
larly, 11/16 dogs with Rocky Mountain spotted fever
had serum antiplatelet antibodies and all 15 dogs
infected experimentally with Rickettsia rickettsii devel-
oped such antibodies by day 26 post infection [67].
The role of the immune system in the pathogenesis of
the haemolytic anaemia that characterizes canine Babe-
sia infection has been investigated. Studies of Babesia
gibsoni-infected dogs in Japan demonstrated the pre-
sence of IgG and IgM red cell-associated antibodies and
the specificity of these antibodies for erythrocyte mem-
brane antigens [73]. A recent European study has sug-
gested that Coombs test positivity is more likely to be
associated with Babesia vogeli infection rather than that
caused by Babesia canis [74], although an earlier study
from North America reported Coombs positivity in 25/
28 cases of B. gibsoni infection and 6/9 cases of B. canis
infection [75]. In contrast, canine haemoplasma infec-
tions do not appear to act as a trigger for immune-
mediated haemolytic anaemia in this species [76]. The
thrombocytopenia that occurs in canine babesiosis may
also in part have an immune-mediated pathogenesis and
platelet-bound antibodies have been demonstrated in B.
gibsoni-infected dogs [77].
Dogs infected experimentally with Bartonella vinsonii
subsp. berkoffii developed mild cyclical or sustained
immunosuppression related to a reduction in circulating
CD8
+ T lymphocytes, but had elevation of CD4
+ T cells
and reduced B cell expression of MHC class II within
lymph nodes [78,79]; however, there remains little
known of the immune response to Bartonella in the
dog.
A recent study of Bernese Mountain dogs, a breed
predisposed to borreliosis and the proposed associated
glomerulopathy; has shown that deficiency of the third
component of complement does not appear to underlie
either predisposition [80]. The immune response occur-
ring within the synoviae of dogs with borreliosis has not
yet been well-characterized, but IL-8 expression has
been defined [81].
Vaccination for canine vector-borne diseases
This section summarizes the current commercially-pro-
duced vaccines designed to limit these infections in the
dog, but does not generally review the numerous devel-
opmental studies of vaccine candidates. Perhaps the
most widely available are the Borrelia vaccines that are
sold in North America and Europe [82]. These are
either adjuvanted whole cell lysates (e.g. Merilyme, Mer-
ial; LymeVax, Fort Dodge) or vaccines containing a
recombinant version of the outer surface protein (Osp)
A of the organism that are adjuvanted (e.g. ProLyme,
Intervet-Schering Plough) or non-adjuvanted (e.g.
Recombitek Lyme, Merial). Most whole cell bacterins
are based on Borrelia burgdorferi sensu stricto, but one
European vaccine includes Borrelia garinii and Borrelia
afzelii which are more relevant species in that area (Bio-
can B, Bioveta). The major serological response to the
whole cell vaccines is to the OspA and OspC proteins.
The OspA antibodies are bactericidal and prevent re-
infection by killing the spirochaetes in the gut of the fed
tick via a complement-dependent mechanism. However,
these vaccines fail to protect 20-40% of vaccinated dogs
from Borrelia infection, which is suggested to reflect the
possibilities that: (1) the organism down-regulates OspA
expression when a tick commences feeding, (2) the bor-
reliacidal anti-OspA antibodies may be genospecies spe-
cific, or (3) that the tick may carry an OspA-negative
Borrelia [83].
Recombinant OspC vaccines are not licensed, but
have been shown experimentally to inhibit colonization
of the tick salivary gland, thereby blocking transmis-
sion to the vertebrate host. OspC is expressed both in
the tick midgut and salivary gland and in the early
stages of infection in the host. A bivalent B. burgdor-
feri bacterin (Nobivac Lyme, Intervet-Schering Plough)
containing isolates that engender both OspA and
OspC antibodies has recently been tested in dogs chal-
lenged 1 year post vaccination with Borrelia-infected
ticks. Compared with unvaccinated controls, vaccinates
remained free of joint infection, lameness and synovi-
tis, did not seroconvert to infection-specific antigens
(determined by western blotting and use of the Idexx
SNAP 4Dx
® test kit) and cleared Borrelia organisms
from the skin adjacent to tick attachment sites by 2
months post exposure [83].
The major consideration related to these non-core
Borrelia vaccines is that of when their administration
m i g h tb ea p p r o p r i a t e ;i nas i t u a t i o nw h e r ee x p o s u r e
(seropositivity) is far more common than clinically sig-
nificant disease [84]. The decision to use such products
in an individual dog should be based upon knowledge of
the geographical distribution of the causative organism,
the particular species of Borrelia present in that region
and whether there is vaccinal cross-protection, and the
lifestyle and exposure risk (e.g. exercise in wooded areas
that are home to Ixodes ticks) of that animal [85]. The
products all have 1 year licensed duration of immunity
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control of exposure to ectoparasites.
In Europe, two commercially produced vaccines
against canine babesiosis are available. The first is a
saponin-adjuvanted vaccine containing soluble parasite
antigens (SPA) produced by B. canis (Pirodog, Merial)
with a licensed duration of immunity of 1 year. The vac-
cine is unlikely to cross-protect against other Babesia
species. A saponin adjuvanted bivalent vaccine contain-
ing SPA produced by B. canis and Borrelia rossi (Nobi-
vac Piro, Intervet-Schering Plough) has been shown to
provide protection against homologous and heterolo-
gous challenge. Vaccinated beagle dogs challenged with
B. rossi shortly after the last of a series of vaccines had
reduction in clinical signs, parasitaemia and plasma con-
centrations of SPA compared with unvaccinated con-
trols [86]. In contrast, vaccinated dogs challenged with
B. canis have reduction in clinical signs and plasma
SPA, but not parasitaemia [87]. This suggests that the
vaccine may have different protective effects - inhibiting
infection and disease in the case of B. rossi challenge,
but inhibiting severity of clinical disease without redu-
cing parasitaemia following challenge with B. canis.T h e
latter may occur if the vaccine-induced antibodies were
able to prevent the initial vasodilatory shock that leads
to microvascular agglutination and hypercoagulation in
infected dogs. This pathogenesis is proposed to underlie
B. canis,b u tn o tB. rossi infection [88,89]. The vaccine
has a licensed duration of immunity of 6 months and is
also available in South Africa. There are few available
field efficacy data for these vaccines and any risk-benefit
analysis for an individual dog should consider the neces-
sity for biannual administration of an adjuvanted non-
core vaccine. Again, tick control is of much greater
importance than administration of a vaccine for this
disease.
The most interesting vaccines in this group are those
licensed for the protection of dogs from Leishmania
infection in Brazil [90]. Although numerous vaccine
candidates have been tested over many years only two
products are currently available commercially [91].
There have been numerous published studies evaluating
the saponin-adjuvanted vaccine incorporating the fucose
mannose ligand (FML) enriched for the surface glyco-
protein 63 of the parasite (Leishmune
®, Fort Dodge Ani-
mal Health). This product induces protective immunity
with IgG seroconversion and development of a robust
response to intradermal administration of Leishmania
lysates. Vaccinated dogs also have a specific Leishma-
nia-specific IgG subclass profile [92]. Discrimination
between vaccinated and infected dogs is important in a
country where serological screening and culling of dogs
is undertaken by the Ministry of Health [93]. It has
been suggested that the potential for misidentification of
vaccinates has led to reluctance of veterinarians in Brazil
to offer the vaccine, but in reality it appears that the
current serodiagnostic test rarely detects vaccinates [94].
After vaccination, cultures of blood lymphocytes stimu-
lated with Leishmania antigen or FML have higher
expression of IFN-g and a reduced proportion of CD4
+CD25
+ putative Treg cells [95]. Similarly, there are
more CD4
+ T cells in the blood of vaccinated dogs that
co-express IFN-g protein as determined by dual-colour
flow cytometry [96]. There is excellent reported clinical
efficacy and duration of immunity of 1 year. One large
trial was conducted of 550 vaccinates and 588 unvacci-
nated controls subjected to natural challenge by living
in a Leishmania endemic area. Two years post vaccina-
tion, only 1% of vaccinates died from leishmaniosis
(compared with 39% of controls) and only 1.2% of the
vaccinates developed clinical signs of the disease (com-
pared with 20.6% of controls) [97]. Most excitingly,
where the product has been used it has had an impact
on the prevalence of both canine and human infection
in the same area, presumptively due to the effect of the
vaccine in blocking transmission of the parasite [94].
When enriched with a double dose of saponin adju-
vant, the vaccine has also been used successfully as an
adjunct immunotherapeutic agent in dogs being treated
medically with allopurinol or allopurinol in combination
with amphoteracin B. The effect of combined medical
and immunotherapy was to reduce clinical and parasito-
logical signs 3 months after initiating therapy and at 8
months to significantly reduce the proportion of treated
dogs that remained PCR-positive [98]. A second vaccine,
under development for human use, has also been evalu-
ated for immunotherapeutic purposes in affected dogs.
The multicomponent protein vaccine Leish-111f formu-
lated with monophosphoryl lipid A in stable emulsion
(MPL-SE) had greater therapeutic efficacy in dogs with
less severe clinical disease, but treatment with the MPL-
SE adjuvant alone also led to clinical benefit [99].
The second canine Leishmania vaccine available in
Brazil is Leishtec
® (Hertape Calier Saúde Animal SA),
which is a saponin-adjuvanted vaccine containing a
recombinant version of the amastigote-specific A2 anti-
gen of L. donovani. The vaccine has a 1-year duration of
immunity [100]. Beagle dogs receiving this vaccine sero-
convert to the A2 protein but not to entire Leishmania
promastigote extract, enabling distinction between vacci-
nated and infected dogs. Cultured blood lymphocytes
from vaccinated dogs express elevated levels of IFN-g,
but not IL-10 protein as detected by capture immunoas-
say. Fewer vaccinated dogs (28.5% of 7 dogs) developed
clinical signs post experimental challenge than unvacci-
nated dogs (71/5% of 7 dogs), and in vaccinates these
signs developed later (12 months) than in the unvacci-
nated controls (3-6 months) [100].
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for release in 2011. This product (CaniLeish
®;V i r b a cS .
A.) consists of excreted secreted proteins (ESP) from
Leishmania infantum - the dominant antigen of which
is the promastigote surface antigen (PSA). The vaccine
is indicated for the active immunization of Leishmania-
negative dogs from 6 months of age and claims to
reduce the risk of developing active infection and clini-
cal disease. The product has a 1-year duration of immu-
nity. Other European investigations have examined the
LiESAp-MDP vaccine, which contains the 54 kDa
excreted protein of L. infantum adjuvanted with mura-
myl dipeptide. In a field trial of spontaneous infection in
and endemic area of France, the incidence of infection
in 165 vaccinated dogs (2 years post vaccination) was
0.6% versus 6.9% in 175 unvaccinated controls [101].
Although these Leishmania vaccines are adjuvanted and
administered annually, as non-core vaccines there is much
to recommend their use in endemic areas of disease with a
high rate of infection in the human population. There are
excellent field data to support their efficacy and serological
discrimination between vaccinated and infected animals
appears feasible. Again, vaccination should be regarded as
one of multiple strategies (including control of sandfly
exposure and control of stray dogs) in the management of
this disease within the population.
Experimental studies have also addressed the possibi-
lity of producing vaccines against arthropods for the
dog, but these are far from a commercial reality. For
example, naïve dogs vaccinated with extracts of salivary
gland or midgut from R. sanguineus and challenged
experimentally 7 and 21 days post vaccination, showed
reduced tick attachment (for both vaccine extracts),
feeding period and engorgement weight (for salivary
vaccine) and fecundity (for midgut vaccine). In the same
study, a control group of dogs repeatedly exposed to R.
sanguineus also showed transient reductions in these
parameters, suggesting development of a degree of spon-
taneous immunity to the tick [102].
Conclusions
It is clear that our understanding of the pathology and
immunology of the CVBDs lags behind the recent rapid
advances made in the molecular characterization of the
causative organisms, their diagnosis and the epidemiol-
ogy of infection. The tools to accomplish such studies
are now generally available and the development of new
vaccines and immunotherapeutics will require their
application to expand our fundamental knowledge base.
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